ArticleExperimental and therapeutic medicine2025
Blockade of cysteinyl leukotriene receptor 1 alleviates asthma by inhibiting bronchial epithelial cell apoptosis and activating the Nrf2 signaling pathway.
Article in Experimental and therapeutic medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Jiao-Tai-Wan Improves Cognitive Impairment by Regulating Nrf2/ARE/HO-1 Signaling Pathway in APP/PS1 Mice.Neurochemical research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The therapeutic role of blockade of cysteinyl leukotriene receptor 1 (CysLTR1) in asthma has been previously studied. However, the effect of CysLTR1 blockade on bronchial epithelial cell apoptosis and the nuclear factor erythroid-derived 2-related factor 2 (Nrf2) signaling pathway remains unclear. The present study established an ovalbumin (OVA)-induced asthmatic rat model. Varying doses (1, 4 and 30 mg/kg) of montelukast sodium, a specific CysLTR1 antagonist, were used to inhibit CysLTR1 function in an asthmatic rat model. Reverse transcription-quantitative PCR was used to detect the expression levels of CysLTR1, NAD(P)H quinone oxidoreductase 1 (NQO1) and heme oxygenase 1 (HO-1). CysLTR1 and Nrf2 protein expression levels were determined using western blotting. Immunofluorescence assays were used to evaluate the relative fluorescence intensity of Nrf2 in rat lung tissues. Lung tissue histology was assessed through hematoxylin & eosin, alcian blue and periodic acid-Schiff and Masson's trichrome staining assays. The levels of IL-17, IL-4, serum IgE and the reduced/oxidized glutathione ratio were determined using ELISA assay kits. The number of inflammatory cells was analyzed using Wright-Giemsa staining. Bronchial epithelial cell apoptosis was measured using a TUNEL assay. The results indicated that OVA-induced inflammatory responses and increased eosinophil, lymphocyte and macrophage counts were significantly attenuated following blockade of CysLTR1. Downregulated expression of antioxidant genes NQO1 and HO-1 and the reduced GSH/GSSG ratio caused by OVA challenge were restored by blockade of CysLTR1. Additionally, CysLTR1 blockade also reduced collagen deposition, suppressed goblet cell hyperplasia and inhibited bronchial epithelial cell apoptosis in a rat model of asthma. Furthermore, it was demonstrated that the blockade of CysLTR1 could significantly increase Nrf2 expression. In conclusion, the blockade of CysLTR1 could alleviate asthma in an OVA-induced rat model by inhibiting bronchial epithelial cell apoptosis and activating the Nrf2 signaling pathway. These data may potentially provide a theoretical basis for future asthma therapy in a clinical setting.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.